Analyst Price Targets — TOI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 9, 2026 4:43 pm | — | BTIG | $9.00 | $5.85 | StreetInsider | The Oncology Insititute Inc. (TOI) PT Raised to $9 at BTIGMember Login |
| July 6, 2026 12:48 pm | — | Lake Street | $10.00 | $5.53 | TheFly | Oncology Institute initiated with a Buy at Lake Street |
| June 17, 2026 11:18 am | — | Needham | $7.00 | $5.10 | TheFly | Oncology Institute price target raised to $7 from $5 at Needham |
| June 8, 2026 11:16 am | David Larsen | BTIG | $8.00 | $4.87 | TheFly | Oncology Institute price target raised to $8 from $7 at BTIG |
| November 25, 2025 12:12 pm | Matthew Shea | Needham | $5.00 | $3.04 | TheFly | Oncology Institute initiated with a Buy at Needham |
| November 11, 2022 8:45 am | — | Guggenheim | $6.00 | $2.50 | Benzinga | Guggenheim Maintains Buy on The Oncology Institute, Lowers Price Target to $6 |
| August 15, 2022 9:35 am | — | Jefferies | $10.00 | $6.44 | Benzinga | Jefferies Initiates Coverage On The Oncology Institute with Buy Rating, Announces Price Target of $10 |
Latest News for TOI
BlackRock Inc. purchased a new position in shares of The Oncology Institute, Inc. (NASDAQ: TOI) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,749,030 shares of the company's stock, valued at approximately $25,787,000. BlackRock Inc. owned approximately 4.80% of Oncology Institute
Oncology Institute (NASDAQ: TOI - Get Free Report) and RadNet (NASDAQ: RDNT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Analyst Ratings This is a summary of current ratings
Oncology Institute NASDAQ: TOI reported second-quarter revenue growth, positive adjusted EBITDA and an expanded pipeline of value-based oncology contracts as the company announced it has rebranded as Starling Oncology.
CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or “the Company”), one of the largest value-based oncology groups in the United States, announced today that it has rebranded to “Starling Oncology, Inc.™.
CERRITOS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release its second quarter 2026 financial results on Thursday, August 6, 2026, to be followed by a conference call the same day at 5:00 p.m.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TOI.
U.S. House Trading
No House trades found for TOI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.